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Abstract
Background: To evaluate the efficacy and safety of silodosin as a medical expulsive therapy for ureteral stones by
means of a systematic review and meta-analysis.
Methods: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register to identify randomized
controlled trials (RCTs) of silodosin in the treatment of ureteral stones. The reference lists of retrieved studies were
also investigated.
Results: Six RCTs, including 916 participants and comparing silodosin with controls, were used in the meta-analysis.
Silodosin was superior to controls in terms of stone expulsion rate, the primary efficacy end point in all six RCTs
(odds ratio [OR] for expulsion 2.16, 95 % confidence interval [CI] 1.62 to 2.86, p <0.00001). Silodosin was also more
effective for secondary efficacy end points; the stone expulsion time (standardized mean difference [SMD] −3.66, 95 %
CI −6.61 to −0.71; p =0.01) and analgesic requirements (SMD −0.89, 95 % CI −1.19 to −0.60; p < 0.00001) were
significantly reduced compared with those of controls. Other than the incidence of abnormal ejaculation, which
was higher in the silodosin groups (OR 2.84, 95 % CI 1.56 to 5.16, p =0.0006), few adverse effects were observed.
Conclusion: This meta-analysis indicates silodosin is an effective and safe treatment option for ureteral stones
with a low occurrence of side effects.
Keywords: Silodosin, Ureteral stones, Meta-analysis, Randomized controlled trial
Abbreviations: RCT, Randomized controlled trial; OR, Odds ratio; CI, Confidence interval; SMD, Standardized
mean difference; MET, Medical expulsive therapy; α1A-AR, α1A-adrenoceptor
Background
Urolithiasis is a multifactorial disease that is common
in daily urological practice, and is also a substantial
public health problem. After urinary tract infections
and pathologic conditions of the prostate [1], urolithia-
sis is the third most common disease of the urinary
tract, with an estimated prevalence of 2–3 % and a life-
time recurrence rate of approximately 50 % [2, 3]. To
date, minimally invasive therapies, such as extracor-
poreal shock wave lithotripsy, ureterolithotripsy and
percutaneous nephrolithotomy have proved to be ef-
fective treatments in many cases. Nevertheless, these
procedures are expensive and are not without risk [4].
A conservative approach involving close monitoring
can be used in most cases, and is becoming more
popular as a result of advances in pharmacological
therapy, which can reduce symptoms and facilitate
stone expulsion [5, 6]. For example, medical expulsive
therapy (MET) using α-adrenoceptor antagonists has
emerged as an alternative strategy for the initial man-
agement of small distal ureteral stones [7].
Silodosin is a novel highly selective α1A-adrenoceptor
(α1A-AR) blocker: in vitro its α1A-to-1B binding ratio is
extremely high (162:1), suggesting that it has the poten-
tial to reduce dynamic neurally mediated smooth muscle
relaxation in the ureter, while minimizing undesirable
effects on blood pressure regulation [8].
The goal of this study was to perform a meta-analysis
to evaluate the efficacy and safety of silodosin as a
MET for ureteral stones to help address some of the
current controversies over its use for this indication.
* Correspondence: doctorcuiys@163.com
Jitao Wu co-first author.
Department of Urology, Yantai Yuhuangding Hospital Affiliated to Medical
College of Qingdao University, NO.20 East Yuhuangding Road, 264000 Yantai,
China
© 2016 Yang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




MEDLINE (1966 to Jan 2015), EMBASE (1974 to Jan
2015) and the Cochrane Controlled Trials Register
databases were searched to identify randomized con-
trolled trials (RCTs) of silodosin in the treatment of
ureteral stones; we also searched the reference lists of the
retrieved studies. The following search terms were used:
“silodosin”; “ureteral stones”; and “randomized controlled
trial”.
Inclusion criteria and trial selection
Randomized controlled trials that met the following
criteria were included: (1) the study design included
treatment with silodosin; (2) the study provided ac-
curate data that could be analyzed, including the total
number of subjects and the values of each outcome
measured; and (3) the full text of the study could be
accessed. When the same study was published in
more than one journal or in different years, the most
recent publication was used for the meta-analysis. If
the same group of researchers studied a group of
subjects with multiple experiments, then each study
was included. A flow diagram of the study selection
process is presented in Fig. 1.
Quality assessment
The quality of the retrieved RCTs was assessed using the
Jadad scale [9]. All identified RCTs were included in the
meta-analysis, regardless of the quality score. The meth-
odological quality of each study was assessed according
to the means of allocation of participants to the arms of
the study, the concealment of allocation procedures,
blinding and data loss due to attrition. The studies were
then classified qualitatively according to the guidelines
published in the Cochrane Handbook for Systematic
Reviews of Interventions v.5.1.0 [10]. Each study was
rated according to these quality assessment criteria, and
assigned to one of the three following quality categories:
A, if all quality criteria were adequately met the study
was deemed to have a low risk of bias; B, if one or more
of the quality criteria was only partially met or was un-
clear the study was deemed to have a moderate risk of
bias; or C, if one or more of the criteria was not met or
not included the study was deemed to have a high risk
of bias. Differences were resolved by discussion among
the authors.
Data extraction
The following information was collected for each study:
(1) the name of the RCT; (2) the study design and sample
size; (3) the therapy that the patients received; (4) the
country in which the study was conducted; and (5) data
including the stone expulsion rate, stone expulsion time,
analgesics required and incidence of adverse events, in-
cluding abnormal ejaculation in male participants.
Statistical analysis and meta-analysis
The meta-analysis of comparable data was carried out
using RevMan v.5.1.0 (Cochrane Collaboration, Oxford,
UK) [10]. We estimated the relative risk for dichotom-
ous outcomes and the standardized mean difference
(SMD) for continuous outcomes pooled across studies
by using the DerSimonian and Laird random-effects
model [11]. The corresponding 95 % confidence inter-
val (CI) was calculated, if the result of analysis showed
p >0.05, we considered the studies homogeneous and
so chose a fixed-effect model for meta-analysis; other-
wise, a random-effect model was used. We quantified
inconsistency using the I2 statistic, which describes the
proportion of heterogeneity across studies that is not
due to chance, thus describing the extent of true incon-
sistency in results across trials [12]. I2 < 25 % reflects a
small amount of inconsistency and I2 > 50 % reflects
significant inconsistency.
Results
Characteristics of the individual studies
The database search produced 114 articles that could
have been included in our meta-analysis. Based on the
inclusion and exclusion criteria, 99 articles were excluded
after reading the titles and abstracts of the articles; nine
articles were not RCTs. In all, six articles [13–18], report-
ing data from three RCTs that compared silodosin with
tamsulosin, two RCTs that compared silodosin with pla-
cebo and one RCT that compared silodosin with naftopi-
dil were included in the analysis (Fig. 1). The baseline
characteristics of the studies included in our meta-analysis
are listed in Table 1.
Quality of the individual studies
Two of the six RCTs were double-blinded, and included
descriptions of the randomization processes used.
Three RCTs included a power calculation to determine
the optimal sample size (Table 2). The quality of all
identified studies was categorized as A or B, and the
final Jadad score for each study ranged from 3 to 5




Six RCTs with 916 participants (457 in the silodosin
groups and 459 in the control groups, Fig. 3) reported
stone expulsion rate as the primary outcome measure.
According to our analysis, no heterogeneity was found
between the trials (P = 0.39) (Fig. 3), and a fixed-effects
model was thus chosen for the analysis. Silodosin
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showed a significantly superior stone expulsion rate
compared with controls (OR 2.16, 95 % CI 1.62 to 2.86;
p <0.00001).
Stone expulsion time
Four RCTs with 541 participants (270 in the silodosin
groups and 271 in the control groups, Fig. 3) reported
stone expulsion times as a secondary outcome. According
to our analysis, heterogeneity was found between the trials
(P = 0.0001). A random-effects model was chosen for the
analysis. The stone expulsion time was significantly
shorter in the silodosin groups than controls (SMD −3.66,
95 % CI −6.61 to −0.71; p =0.01).
Analgesia required
Two of the RCTs (consisting of 367 participants, with
185 in the silodosin groups and 182 in the control
groups, Fig. 3) reported the analgesics required during
stone expulsion. According to our analysis, no hetero-
geneity was found between the trials (P = 0.85). A fixed-
effects model was chosen for the analysis. Expulsion
using silodosin was associated with a significantly lower
analgesic requirement than that in controls (SMD −0.89,
95 % CI −1.19 to −0.69; p <0.00001).
Side effects and safety
Abnormal ejaculation
Six RCTs with 916 participants (457 in the silodosin
groups and 458 in the control groups, Fig. 3) reported the
incidence of abnormal ejaculation (Fig. 4). The effect size
for the purposes of meta-analysis was denoted as the OR.
According to our analysis based on a fixed-effects model,
no heterogeneity was found between the trials (P = 0.47).
The pooled estimate of OR was 2.84 (95 % CI 1.56 to 5.16,
p =0.0006). This suggests that abnormal ejaculation was
more common among patients treated with silodosin than
among control-treated patients.
Subgroup analysis
We divided the included studies into three groups on
the basis of the treatment given to the control groups:
tamsulosin, naftopidil or inactive placebo. According to
Fig. 1 A flow diagram of the study selection process. RCT: randomized controlled trial
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our analysis, no heterogeneity was found between the
trials (P > 0.05); therefore, we chose a fixed-effects model
for the analysis. Stone expulsion rates were significantly
higher in those treated with silodosin compared with
tamsulosin (OR 1.65, 95 % CI 1.12 to 2.43; p =0.01),
naftopidil (OR 2.83, 95 % CI 1.80 to 4.45; p <0.00001) or
inactive placebo (OR 3.36, 95 % CI 1.13 to 9.96; p =0.03,
Fig. 5).
We further divided the included studies into two groups
according to stone location: proximal or distal. According
to our analysis, no heterogeneity was found between
the trials (P > 0.05); therefore, a fixed-effects model was
chosen. Stone expulsion rates were significantly higher
in those treated with silodosin compared with control
in spite of the stone location. (proximal OR 2.1, 95 %
CI 1.12 to 3.92; p =0.02 or distal OR 2.53, 95 % CI 1.61
to 3.99; p <0.00001, Fig. 6).
Discussion
The introduction of more effective drugs has seen sig-
nificant improvements in the medical management of
ureteral stones. The likelihood of a ureteral stone pass-
ing depends on several factors, which include the stone
size and location, and the condition of the ureter [19].
The stimulation of the α1-AR in the ureter increases
the force of ureteric contraction and the frequency of
ureteric peristalsis. Blockade of the α1-AR inhibits basal
tone, reduces peristaltic amplitude and frequency, and
decreases intraluminal pressure while increasing the
rate of fluid transport and the chances of stone expul-
sion. Expression of the α1A- and α1D-AR subtypes is
greater in the distal ureter [20]. Silodosin is a highly
selective α1A-AR blocker, and it has been demonstrated
in vitro that silodosin’s α1A-to-1B binding ratio is
extremely high (162:1).
Our meta-analysis found that silodosin 8 mg/day for
3–8 weeks is superior to controls (tamsulosin 0.4 mg/day,
naftopidil 50 mg/day or inactive placebo) in improving the
stone expulsion rate, reducing the stone expulsion time and
analgesic requirements. According to our analysis, no het-
erogeneity was found between the trials, allowing us to use
a fixed-effects model for the analysis. We may therefore
conclude that silodosin 8 mg/day treats stones more














silodosin blank control Japan 95 92 Oral 8 wk 8mg/d symptomatic unilateral ureteral
calculi of less than 10 mm
Tsuzaka Y
2011




silodosin tamsulosin India 50 50 Oral 4 wk 8mg/d unilateral, uncomplicated middle
or lower ureteral stones ≤10 mm
Dell'Atti L
2014
silodosin tamsulosin Italy 68 68 Oral 3 wk 8mg/d single, unilateral, radiopaque,
proximal ureteral stone
(range 4–10 mm in size)
Sur RL
2014




silodosin tamsulosin India 90 90 Oral 4 wk 8mg/d distal ureteric stones of size
5–10 mm









Statistical analysis Level of quality Jadad
Score(5-point)
Itoh Y 2011 B B A 6 NO Student’s t-test B 3
Tsuzaka Y 2011 B B A 10 NO Student’s t-test B 3
Guptas S 2013 A B A 0 NO Student’s t-test A 4
Dell'Atti L 2014 B A A 3 YES Student’s t-test A 4
Sur RL 2014 A A A 6 YES Wilcoxon test A 5
Kumar S 2015 A A A 6 YES chi-square test A 5
A - all quality criteria met (adequate): low risk of bias. B - one or more of the quality criteria only partly met (unclear): moderate risk of bias
C - one or more criteria not met (inadequate or not used): high risk of bias
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effectively than tamsulosin 0.4 mg/day, naftopidil 50 mg/
day or placebo. Our subgroup analysis showed that stone
expulsion rates were significantly higher in those treated
with silodosin compared with those treated with a control,
regardless of stone location. It is worth noting that stone
expulsion rates ranged from 57.7 % to 80.9 % in cases in-
volving proximal ureteral stones, and 69.8 % to 93.8 % in
distal ureteral stones. Therefore, it seems that the stone ex-
pulsion rate for distal ureteral stones is higher than for
proximal ureteral stones. Stone size has been identified as
Fig. 3 Forest plots showing changes in (a) the stone expulsion rate, (b) stone expulsion time and (c) analgesics were required. MH: mantel
haenszel, CI: confidence interval, SD: standard deviation, IV: inverse variance
Fig. 2 Funnel plot of the studies represented in our meta-analysis. OR: odds ratio, SE: standard error
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an important predictive factor for expulsion: the trials we
chose examined those ≤10 mm in diameter, so we cannot
draw any conclusions about the role of silodosin in the
treatment of larger ureteral calculi.
The α1A/D selective AR-blocker tamsulosin is recog-
nized as a safe and effective drug that also enhances
spontaneous passage of distal ureteral stones ≤10 mm in
diameter [21]. Recent studies have demonstrated that
the α1A subtype plays the most important role in medi-
ating phenylephrine-induced contraction of the isolated
human ureter [22]. Kobayashi et al. found that silodosin
enhanced noradrenaline-induced contraction of the
human ureter more than the selective α1D-AR antagon-
ist BMY-7378 [23]. The mechanism of action of silodo-
sin presumably includes blockade of the α-adrenergic
receptors, thereby relaxing the ureter and potentially
providing a spasmolytic effect [24].
Our meta-analysis suggests that there is a higher inci-
dence of retrograde ejaculation in patients treated with
silodosin than active or inactive controls. The incidence
of side effects was similar to that reported by other au-
thors [25]. Nonetheless, retrograde ejaculation does not
appear to be particularly troublesome, and only a small
proportion of participants enrolled in clinical studies
Fig. 5 Forest plots showing changes in the stone expulsion rate. MH: mantel haenszel, CI: confidence interval (Subgroup analysis results)
Fig. 4 Forest plots showing changes in abnormal ejaculation. MH: mantel haenszel, CI: confidence interval
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who report this adverse effect discontinued treatments
because of it [26]. Furthermore, retrograde ejaculation
resolves completely within a few days of discontinuing
treatment [26]. Silodosin appears to relax the smooth
muscles of the lower urinary tract and the genital tract
enough to induce retrograde ejaculation, reflected in the
finding that patients who had the greatest relief from
lower urinary tract symptoms had a higher likelihood of
retrograde ejaculation. This observation suggests that
retrograde ejaculation is an indirect indicator of the
extent of the smooth muscle relaxation that silodosin
induces. Other than retrograde ejaculation, the type and
incidence of adverse events reported by those taking
silodosin were similar to those taking tamsulosin, naftopi-
dil or an inactive control. Besides, Imperatore V et al. con-
ducted a retrospectively controlled study demonstrated
that MET with silodosin is associated with a lower inci-
dence of side effects related to peripheral vasodilation but
an higher incidence of retrograde ejaculation when com-
pared to tamsulosin [27].
Our meta-analysis was based on data collected entirely
from RCTs that we considered to be at low risk of bias.
This suggests that our findings could be sufficiently sound
to inform everyday clinical practice. Importantly, however,
the number of included studies was small and there were
a variety of control groups; therefore, a certain amount of
clinical heterogeneity seems inevitable. Furthermore, we
cannot account for the possible influence of unpublished
studies, which could have introduced an unrecognized
bias into our analysis. The longer-term efficacy and safety
of silodosin cannot therefore be extrapolated from our
findings. More high-quality trials with larger sample sizes
are needed to establish fully the role of silodosin in the
treatment of distal ureteral stones.
Conclusions
This meta-analysis indicates silodosin is an effective and
safe treatment option for ureteral stones with a low
occurrence of side effects.
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